Menu Search
Equities

Lexicon Pharmaceuticals Inc

LX31:BER

Lexicon Pharmaceuticals Inc

Actions
  • Price (EUR)0.7245
  • Today's Change-0.021 / -2.75%
  • Shares traded2.03k
  • 1 Year change-28.27%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 11:22 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.

  • Revenue in USD (TTM)5.23m
  • Net income in USD-216.39m
  • Incorporated1995
  • Employees285.00
  • Location
    Lexicon Pharmaceuticals Inc2445 Technology Forest Blvd, 11Th FloorTHE WOODLANDS 77381United StatesUSA
  • Phone+1 (281) 863-3000
  • Fax+1 (281) 863-8088
  • Websitehttps://www.lexpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.